Daiichi Sankyo And Merck : Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial

Daiichi Sankyo and Merck's ifinatamab deruxtecan (I-DXd) demonstrated promising efficacy in the Phase 2 IDeate-Lung01 trial for previously treated extensive-stage small cell lung cancer (ES-SCLC), a highly aggressive cancer with significant unmet medical need. The trial reported a 48.2% objective response rate (ORR) among 137 patients, with a median overall survival (OS) of 10.3 months, supporting progression to further randomized studies. This positive data reinforces the drug's potential, building on its August 2025 FDA Breakthrough Therapy Designation for ES-SCLC.

Analysis

Daiichi Sankyo and Merck & Co. have reported clinically meaningful results from the Phase 2 IDeate-Lung01 trial for ifinatamab deruxtecan (I-DXd) in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). The study demonstrated a confirmed objective response rate (ORR) of 48.2% and a disease control rate of 87.6% in 137 patients, as assessed by blinded independent central review. These efficacy metrics are significant given that ES-SCLC is an aggressive malignancy with a low survival rate. The potential first-in-class B7-H3 directed antibody drug conjugate (ADC) also achieved a median overall survival (OS) of 10.3 months and a median progression-free survival (PFS) of 4.9 months. These outcomes reinforce the potential of the drug, which was previously granted Breakthrough Therapy Designation by the FDA, and provide a strong rationale for advancing to a randomized, controlled evaluation, a critical step toward potential regulatory approval.

Key Decisions for Investors

• Investors should view these positive Phase 2 results as a significant de-risking event for the I-DXd program, strengthening the long-term growth outlook for Daiichi Sankyo's and Merck's oncology pipelines.
• The next key catalyst to monitor is the announcement and design of the subsequent randomized, controlled trial, as its structure and endpoints will be critical for the path to commercialization.
• While the 48.2% response rate is strong, the median duration of response of 5.3 months warrants attention, and investors should assess the therapy's durability against existing and emerging competitors in the SCLC space as more data becomes available.